Effect of Lidocaine Through Gastric Tube on PONV
Effect of Lidocaine Applied Via Nasogastric Tube on Postoperative Nausea and Vomiting in Obese Patients Undergoing Bariatric Surgery
The goal of this clinical trial is to learn if intragastric administration of lidocaine can reduce postoperative nausea and vomiting in obese patients undergoing laparoscopic sleeve gastrectomy. The main question it aims to answer is:
Does administering 0.5% lidocaine via an orogastric tube reduce the incidence of postoperative nausea and vomiting (PONV) in the post-anesthesia care unit and within the first 24 hours after surgery compared to a placebo (normal saline)?
Researchers will compare the Lidocaine Group to the Placebo Group to see if the intervention lowers the PONV incidence.
Participants will:
- Receive the assigned study solution (either 0.5% lidocaine 20ml or normal saline 20ml) through an orogastric tube upon surgery completion and before extubation.
- Have their gastric tube clamped for 5 minutes to ensure mucosal exposure before removal.
- Undergo standardized total intravenous anesthesia and perioperative management according to the study protocol.
- Be assessed for nausea, vomiting, and other outcomes at specified time points postoperatively in the recovery room and at 6, 12, and 24 hours.
Studie Overzicht
Toestand
Toestand
Conditie
Conditie
Interventie / Behandeling
Interventie / Behandeling
Gedetailleerde beschrijving
Postoperative nausea and vomiting (PONV) is a common complication following bariatric surgery, with incidence rates reaching up to 30-80%. In bariatric surgical patients, the burden of PONV is particularly high due to multiple risk factors, including surgical trauma to upper GI system, frequent opioid use, increased intra-abdominal pressure, altered gastric anatomy, and heightened sensitivity of gastrointestinal reflex pathways. Effective prevention and treatment of PONV in this population therefore represents a major clinical priority.
Current prophylactic strategies rely primarily on pharmacological agents such as serotonin (5-HT3) receptor antagonists, corticosteroids, dopamine antagonists, and multimodal combinations. Despite these measures, the incidence of breakthrough PONV remains significant, underscoring the need for additional safe, effective, and inexpensive interventions.
Lidocaine, traditionally used as a local anesthetic and antiarrhythmic, has gained attention in perioperative medicine for its systemic anti-inflammatory, analgesic, and opioid-sparing effects when administered intravenously. Evidence suggests that perioperative lidocaine can improve gastrointestinal motility, reduce visceral hypersensitivity, and facilitate earlier return of bowel function. These properties raise the possibility that lidocaine may also influence nausea and vomiting pathways by attenuating vagal afferent signaling, reducing local gastric irritation, and dampening inflammatory responses within the gastrointestinal mucosa.
Delivering lidocaine directly into the gastric cavity via an orogastric (OG) tube represents a novel and pragmatic approach. Unlike intravenous administration, intragastric instillation allows targeted mucosal exposure, potentially reducing afferent vagal stimulation that triggers nausea and vomiting. This method is technically simple, inexpensive, and feasible within the routine workflow of bariatric surgery, as OG tubes are already placed for intraoperative management.
This study aims to evaluate whether the administration of lidocaine via nasogastric tube can reduce the incidence of postoperative nausea and vomiting (PONV) in patients undergoing bariatric surgery. If effective, local lidocaine administration may serve as a simple, low-cost, and readily adoptable strategy to improve postoperative outcomes in bariatric surgery patients. This approach could expand the multimodal anesthesia regimen and optimize the enhanced recovery after surgery (ERAS) pathway for bariatric procedures.
Studietype
Studietype
Inschrijving (Geschat)
Inschrijving
Fase
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
Studiecontact
- Naam: Siying He
- Telefoonnummer: +86 18209610221
- E-mail: 1342850868@qq.com
Studie Locaties
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750000
- Werving
- General Hospital of Ningxia Medical University
-
Contact:
- General Hospital of Ningxia Medical University
- Telefoonnummer: +86-0951-4091488
- E-mail: 1342850868@qq.com
-
-
Deelname Criteria
Geschiktheidscriteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- Adults aged between 18 and 65 years old;
- American Society of Anesthesiologists (ASA) physical status classification II - III;
- Planned to undergo primary elective laparoscopic sleeve gastrectomy with general anesthesia;
- Capable of giving informed consent.
Exclusion Criteria:
- Known allergy, hypersensitivity or contraindication to lidocaine or amide - type local anesthetics;
- Previous significant liver or kidney dysfunction (e.g., ALT/AST > 3 times the upper limit of normal, GFR < 30 mL/min);
- History of epilepsy, cardiac conduction abnormalities or previous diagnosis of malignant hyperthermia;
- Pregnancy or lactation;
- Patients who received systemic lidocaine treatment during the operation;
- History of severe postoperative nausea and vomiting (PONV) or motion sickness, requiring multiple prophylactic medications;
- Emergency or revision bariatric surgery.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Aantal wapens
Wapens en interventies
Deelnemersgroep / ArmDeelnemersgroep / Arm |
Interventie / BehandelingInterventie / Behandeling |
|---|---|
|
Experimenteel: Lidocaine
Lidocaine is administered via a gastric tube.
|
Upon completion of the surgery and before extubation, 20 ml of 0.5% lidocaine should be administered through the pre - inserted orogastric tube.
The gastric tube should be clamped for 5 minutes to ensure sufficient mucosal exposure, and then removed before extubation.
|
|
Experimenteel: Normal Saline
Administer normal saline through the gastric tube.
|
Before extubation after the surgery is completed, administer 20 ml of normal saline through the pre - inserted orogastric tube.
Clamp the gastric tube for 5 minutes to ensure sufficient mucosal exposure, and then remove the tube before extubation.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
The incidence of postoperative nausea and vomiting (PONV) in the post - anesthesia care unit and within 24 hours after surgery.
Tijdsspanne: Within 24 hours after the operation
|
Within 24 hours after the operation
|
Secundaire uitkomstmaten
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Degree of postoperative nausea and vomiting
Tijdsspanne: 6 hours, 12 hours, and 24 hours after surgery
|
The severity of nausea and vomiting was assessed using the Numerical Rating Scale at 6 hours, 12 hours, and 24 hours after surgery, respectively.
A score of 0 indicated no nausea or vomiting, and a score of 10 indicated the most severe nausea or vomiting.
|
6 hours, 12 hours, and 24 hours after surgery
|
|
Incidence rates of simple vomiting, simple nausea, and their combination during the postoperative anesthesia recovery room period and within 24 hours after surgery.
Tijdsspanne: Within 24 hours after the operation
|
Within 24 hours after the operation
|
|
|
Use rescue antiemetics
Tijdsspanne: Within 24 hours after surgery.
|
Use of emergency antiemetic drugs and time nodes after surgery.
|
Within 24 hours after surgery.
|
|
Opioid use within 24 hours after surgery
Tijdsspanne: 24 hours after surgery
|
The amount of opioids used 24 hours after surgery.
|
24 hours after surgery
|
|
Time of first tolerable oral intake
Tijdsspanne: Within 72 hours after surgery.
|
The time of the first oral tolerance to eating after surgery
|
Within 72 hours after surgery.
|
Medewerkers en onderzoekers
Sponsor
Sponsor
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Studie start
Primaire voltooiing (Geschat)
Primaire voltooiing
Studie voltooiing (Geschat)
Studie voltooiing
Studieregistratiedata
Eerst ingediend
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Eerst geplaatst
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update geplaatst
Laatste update ingediend die voldeed aan QC-criteria
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Postoperatieve complicaties
- Pathologische processen
- Tekenen en symptomen, spijsvertering
- Braken
- Misselijkheid
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Postoperatieve misselijkheid en braken
- Organische chemicaliën
- Farmaceutische voorbereidingen
- Anilides
- Amides
- Aniline -verbindingen
- Amines
- Acetaniliden
- Crystalloid -oplossingen
- Isotone oplossingen
- Oplossingen
- Lidocaïne
- Zoutoplossing
Andere studie-ID-nummers
Andere studie-ID-nummers
- Siying He-2026-01
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .